Why is $AQST moving today? · SEC 8-K archive

$AQST SEC Filing Alert & Real-Time AI Stock Impact Analysis

T0 SEO archive for $AQST: filings appear instantly. AI score, direction and bullet analysis unlock publicly after 4 hours (VIP sees them live).

← All archive signals

FAQ: $AQST filing catalyst

Why did $AQST trigger an AI stock catalyst alert?

$AQST triggered a Stock Catalyst AI alert on 2026-11-03 00:00:00 UTC for a SEC 8-K filing (AI Score: -2.5/10). Headline: Aquestive Reports Q3 Revenue Decline to $7.56M; Anaphylm PDUFA Set for March 16, 2027. Key points: - Q3 revenue fell 41% YoY to $7.56M vs $12.81M in Q3 2025. - Net loss widened slightly to $16.50M ($0.13 per share) compared to $15.45M ($0.14 per share) in prior-year period. - FDA accepted Anaphylm NDA resubmission with a PDUFA goal date of March 16, 2027.

How did $AQST stock react after the SEC filing?

After the SEC 8-K for $AQST, observed market reaction: T0 price $3.88. Past moves do not guarantee future results.

Where can I get real-time $AQST SEC filing alerts?

Stock Catalyst AI pushes real-time SEC 8-K alerts for $AQST via Telegram and the VIP Web Terminal from €10/month.

$AQST

$AQST – Aquestive Reports Q3 Revenue Decline to $7.56M; Anaphylm PDUFA Set for March 16, 2027

Aquestive Therapeutics, Inc.

2026-11-03 00:00:00 UTC · SEC 8-K · All $AQST

Unlocked archive · Analyzed in <2s at T0

Bearish AI Sentiment (-2.5 / 10)

Q3 revenue fell 41% YoY to $7.56M vs $12.81M in Q3 2025.
Net loss widened slightly to $16.50M ($0.13 per share) compared to $15.45M ($0.14 per share) in prior-year period.
FDA accepted Anaphylm NDA resubmission with a PDUFA goal date of March 16, 2027.

Unlock Live VIP Terminal & Telegram – €10/mo Original filing →